Skip to main navigation Skip to search Skip to main content

PRV-031-003: A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR NonBinding, Anti-C03 Monoclonal Antibody, in Children and Adolescents with Recent-Onset Type

Project: Research

Project Details

StatusActive
Effective start/end date06/10/21 → 03/1/27

Funding

  • Psi: $131,753.48